UBS Oncology Impact Fund L.P.
SEC CIK 1691428 · EDGAR
BoughtSold
Most active insiders at HOWL, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | EVNIN LUKE | Dir | — | $3.26M |
| 2 | MPM BioVentures 2014 LLC | 10% | — | $1.09M |
| 3 | RA CAPITAL MANAGEMENT, L.P. | 10% | — | $963.9K |
| 4 | UBS Oncology Impact Fund L.P. | 10% | — | $824.5K |
| 5 | MPM Asset Management Investors BV2014 LLC | 10% | — | $528.5K |
| 6 | MPM Oncology Innovations Fund GP LLC | 10% | — | $528.1K |
| 7 | MPM BioImpact LLC | Former 10% Owner | — | $479.1K |
| 8 | MPM ONCOLOGY INNOVATIONS FUND LP | 10% | — | $391.6K |
| 9 | MPM BioVentures 2014, L.P. | 10% | — | $241.3K |
| 10 | MPM BioVentures 2014 (B), L.P. | Former 10% Owner | — | $183.3K |
Transactions 4
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MI | 2025-12-01 | 2025-11-26+ | HOWL | Werewolf Therapeutics, Inc. | UBS Oncology Impact Fund L.P. | 10% | S - Sale | $0.9643 | -141.9K | 5.07M | -3% | -$136.9K |
| MI | 2025-11-12 | 2025-11-07+ | HOWL | Werewolf Therapeutics, Inc. | UBS Oncology Impact Fund L.P. | 10% | S - Sale | $1.13 | -213.5K | 5.73M | -4% | -$241.3K |
| MI | 2025-10-29 | 2025-10-27+ | HOWL | Werewolf Therapeutics, Inc. | UBS Oncology Impact Fund L.P. | 10% | S - Sale | $1.62 | -276.0K | 6.44M | -4% | -$446.4K |
| M | 2021-09-02 | 2021-08-31+ | CGEM | Cullinan Therapeutics, Inc. | UBS Oncology Impact Fund L.P. | 10% | S - Sale | $29.50 | -24.3K | 7.74M | -0.3% | -$717.2K |
Purchase Sale Sale after option exercise All abbreviations